Dulaglutide

2025年5月26日，美国旧金山和中国苏州——信达生物制药集团（  香港联交所股票代码：01801），一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布：胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂，玛仕度肽，在中国超重或肥胖受试者中的III期临床研究（GLORY-1）结果近日在国际知名期刊《新英格兰医学杂志》（The New England Journal of Medicine, NEJM）全文在线发表（点击文末阅读原文查看文章），并特配专家评述。本文第一作者分别为北京大学人民医院纪立农教授和河南科技大学附属第一医院姜宏卫教授，另外纪立农教授和信达生物制药集团钱镭博士为本文共同通讯作者。这是全球首个且唯一申报上市的GCG/GLP-1双受体激动减重降糖药物的临床研究第一次登顶医学权威学术期刊，将改写国内外超重和肥胖疾病的临床治疗和指南。在中国代谢和内分泌疾病领域，第一次有创新药临床研究结果发表在全球最权威期刊上，代表了中国药物研发能力与生物科技创新水平迈上了新台阶。针对这项最新发布的重磅研究，哈佛大学医学院波士顿布莱根妇女医院 Vanita R. Aroda 教授与科罗拉多大学安舒茨医学院 Leigh Perreault 教授同步在《新英格兰医学杂志》发布评论指出，GLORY-1研究中展现出的中国人特点与西方人不同，在更加年轻的人群中，代谢异常比例不低甚至更高，而GCG/GLP-1双受体激动剂治疗不仅能显著降低体重和BMI，更能全面改善肥胖相关全身性健康风险；此外中国肥胖干预需结合本土人群特征实施差异化策略，重点关注肝脏健康与血脂管理。中国肥胖日益年轻化，社会负担更重，因此要更早干预，并且从早期干预也会带来更大获益。对于肥胖领域不断涌现的新疗法，两位专家认为药物疗法仅是肥胖防控的一环，需与公共卫生政策协同构建综合防治体系，以更有效应对全球肥胖负担。玛仕度肽预计今年在国内上市，将获批减重降糖两项适应症。因出色的减重疗效和全面的代谢获益，玛仕度肽获评2025年全球十大最受期待药物之一（FIERCE Pharma 2025）。此前临床研究表明i,ii：使用玛仕度肽体重降幅达21%，降低肝脏脂肪含量超 80%，腰围减少达11cm，颈围减少接近3cm，兼顾改善血压、血脂、血尿酸和转氨酶水平等多重代谢指标。玛仕度肽还能有效降低糖化血红蛋白达2.15%，且耐受性良好。此次入选《新英格兰医学杂志》的研究为玛仕度肽一项低剂量减重注册临床研究GLORY-1。GLORY-1研究共入组610例肥胖（BMI≥28 kg/m2）或超重（24kg/m2≤ BMI ＜28 kg/m2）并伴有至少一种肥胖相关并发症的受试者，随机接受玛仕度肽 4 mg、6 mg和安慰剂，每周一次、皮下注射给药48周。研究主要终点为第32周时体重较基线的百分比变化和体重较基线降幅≥5%的受试者比例。受试者基线平均体重为87.2 kg，基线平均BMI为31.1 kg/m2。研究结果显示，各剂量玛仕度肽相较安慰剂均可显著降低体重。基于疗效估计目标:第32周时，玛仕度肽4 mg、6 mg和安慰剂组体重较基线百分比变化的均值分别为−10.97%、−13.38%和−0.24%；第48周时分别为−12.05%、−14.84%和−0.47%。第32周时，玛仕度肽4 mg、6 mg和安慰剂组体重较基线降幅≥5%的受试者比例分别达76.3%、84.0%和10.9%。第48周时，玛仕度肽4 mg、6 mg和安慰剂组体重较基线降幅≥15%的受试者比例分别达37.0%、50.6%和2.1%。研究的主要终点及所有关键次要终点结果均显示了玛仕度肽任一剂量组相较安慰剂组具有统计学意义的优效性，p值均小于0.001(主要结果如下)。玛仕度肽显著降低血压、血脂（甘油三酯、总胆固醇和低密度脂蛋白胆固醇）、血尿酸、转氨酶水平等心血管代谢指标。此外，玛仕度肽显著降低了超重或肥胖受试者的肝脏脂肪含量。在基线肝脏脂肪含量≥5%的受试者中，第48周时，玛仕度肽4 mg、6 mg和安慰剂组受试者全肝平均脂肪含量相对基线的百分比变化均值分别为−63.26%、−73.18%和+8.20%；在基线肝脏脂肪含量≥10%的受试者中，第48周时，玛仕度肽4 mg、6 mg和安慰剂组受试者全肝平均脂肪含量相对基线的百分比变化均值分别为−65.85%、−80.24%和−5.27%。玛仕度肽总体耐受性和安全性良好。玛仕度肽组整体安全性特征与玛仕度肽的既往研究和其他GLP-1受体激动剂类药物相似。最常报告的治疗期不良事件包括恶心、腹泻和呕吐，大多为轻度或中度。研究期间未见心血管风险增加的安全性信号。该研究的牵头研究者、北京大学人民医院纪立农教授表示：“长期以来，全球肥胖诊疗指南主要基于白人人群数据，对亚洲人群的适用性存在偏差。与此同时，相比欧美人群，中国超重肥胖人群有着独特的疾病特点及治疗需求，亟需以中国证据，指导中国超重肥胖人群的体重管理。对于中国大多数超重和轻度肥胖症患者，减重目标应设定为：在3-6个月之内至少将体重降低5%-15%并维持；对于中、重度肥胖症患者则可设定更高的减重目标。GLORY-1研究人群全部来自中国人群，符合上述中国人群减重目标的设定，研究中玛仕度肽的减重数据十分令人振奋，近半数患者减重幅度＞15%，这提示，对于超重、轻度和中重度肥胖患者，玛仕度肽均能够帮助其显著控制体重，完成减重目标。玛仕度肽GLORY-1研究见刊于全球最权威的临床医学期刊《新英格兰医学杂志》，不仅代表了中国在内分泌代谢领域的创新研究成果得到了国际认可，也再次证实中国创新药物的研发能力与生物科技创新水平已走在了全球前列。玛仕度肽的研发成功将加速本土企业在肥胖管理领域的布局，为中国超重肥胖患者提供更具个性化的全周期管理方案。”信达生物制药集团钱镭博士表示：“玛仕度肽是全球GCG/GLP-1双受体激动剂中第一个即将获批的分子，其注册研究GLORY-1在《新英格兰医学杂志》的发表为中国内分泌代谢领域新药临床研究实现了零的突破，也为中国超重或肥胖受试者的的临床治疗提供了高质量的循证医学证据，未来必将改写指南与临床诊疗实践。这一学术成果同时证明了我国研究者卓越的临床研究水平和中国创新制药企业扎实的创新研发能力。玛仕度肽即将在中国获批上市，我们期待玛仕度肽为中国超重或肥胖人群带来更多和更优的治疗选择，为生活更添美好。作为创新药企业，信达生物积极响应国家号召，与有关各方携手同行，以前沿医学成果助力全民科学减重、推进健康中国建设。”关于肥胖/超重- 滑动查看更多介绍 -肥胖是一项成因复杂的慢性代谢性疾病，是导致糖尿病、脂肪肝、心脑血管疾病、肾病、关节疾病、呼吸睡眠障碍和癌症等一系列疾病的重要病因或危险因素。随着经济发展和生活方式的改变，中国肥胖症的患病人数已跃居世界首位iii。在较为严重的肥胖患者中，心血管疾病、糖尿病和某些肿瘤的发生率及死亡率明显上升。2019年超重和肥胖导致的死亡在慢性非传染性疾病相关死亡中占比11.1%，相比1990年的5.7%显著增加iv。超重/肥胖已成为一个严重的健康问题，生活方式干预是超重/肥胖者的基础且重要手段，但是仍有相当一部分患者由于种种原因不能达到期望的减重目标，需用药物辅助治疗。传统减肥药减重效果有限，且存在安全性问题，对疗效更好且安全的减肥疗法的临床需求尚未得到满足。关于玛仕度肽（IBI362）- 滑动查看更多介绍 -玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂。作为一种哺乳动物胃泌酸调节素（OXM）类似物，玛仕度肽除了通过激动GLP-1受体促进胰岛素分泌、降低血糖和减轻体重外，还可通过激动GCGR增加能量消耗增强减重疗效，同时改善肝脏脂肪代谢。玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效，以及降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量，以及改善胰岛素敏感性，带来多重代谢获益。玛仕度肽当前共开展了六项III期临床研究，包括：在中国超重或肥胖受试者中开展的III期临床研究（GLORY-1）；在中国中重度肥胖受试者中开展的III期临床研究（GLORY-2）；在中国超重或肥胖合并MAFLD受试者中开展的III期临床研究（GLORY-3）;在初治的中国2型糖尿病患者中开展的III期临床研究（DREAMS-1）；在口服药物治疗血糖控制不佳的中国2型糖尿病受试者中开展的对比玛仕度肽和度拉糖肽的III期临床研究（DREAMS-2）；在中国2型糖尿病合并肥胖的受试者中开展的对比玛仕度肽和司美格鲁肽的III期临床研究（DREAMS-3）。其中，GLORY-1、DREAMS-1和DREAMS-2研究均已达成终点，其他研究还在进行中。此外，玛仕度肽的多项新临床研究计划启动，其中包括治疗青少年肥胖和阻塞性睡眠呼吸暂停（OSA）的两项III期临床研究，以及治疗代谢相关脂肪性肝炎（MASH）、射血分数保留心力衰竭（HFpEF）等新临床研究。关于信达生物- 滑动查看更多介绍 -“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有15个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®）， 雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®），伊基奥仑赛注射液（福可苏®），托莱西单抗注射液（信必乐®），氟泽雷塞片（达伯特®），匹妥布替尼片(捷帕力®)，己二酸他雷替尼胶囊（达伯乐®），利厄替尼片（奥壹新®）和替妥尤单抗N01注射液（信必敏®）。目前，同时还有3个品种在NMPA审评中，4个新药分子进入III期或关键性临床研究，另外还有15个新药品种已进入临床研究。公司已与礼来、罗氏、赛诺菲、Adimab、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守“以患者为中心”，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。   详情请访问公司网站：www.innoventbio.com或公司领英账号：Innovent Biologics。声明：1.信达不推荐任何未获批的药品/适应症使用。2.雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®）和匹妥布替尼片（捷帕力®）由礼来公司研发。参考文献：i. JI L, et al. 1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)[J]. Diabetes, 2024, 73(Supplement_1).ii.Mazdutide reduces body weight in adults with overweight or obesity: a multiple-dose study.2024 EASD Abstract # 734.iii.Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373-92.iv.Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

SAN FRANCISCO and SUZHOU, China, May 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial []. The first authors of this paper are Professor Linong Ji from Peking University People's Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors. This marks the first time that a clinical study of mazdutide, the world's first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China's growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity. Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women's Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively. Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma's 2025 Top 10 Most Anticipated Drugs. In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32. At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses. Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group. The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows). Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators. In addition, mazdutide significantly reduced liver fat content. Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively; Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. Good overall safety and tolerability of mazdutide were reported. The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity. At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study. Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People's Hospital, stated, "For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China's overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity. Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China's innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide's successful development will accelerate domestic enterprises' strategic presence in obesity management, enabling comprehensive, personalized solutions for China's overweight/obese population throughout their treatment journey." Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China's drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide's imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of 'Healthy China 2030' by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. " About Obesity China has the world's largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2]. Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions. About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Mazdutide currently has two NDAs accepted for review by NMPA, including: For chronic weight management in adults with overweight or obesity; For glycemia control in adults with type 2 diabetes. Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D. DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity. Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED